# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Abbott Laboratories is launching Lingo, an over-the-counter glucose monitoring device aimed at non-diabetic consumers, utilizin...
Morgan Stanley analyst Patrick Wood maintains DexCom (NASDAQ:DXCM) with a Equal-Weight and lowers the price target from $132...
Stifel analyst Mathew Blackman maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $145 to $132.
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will s...